ICON has approximately 41,160 employees in 108 locations in 53 countries as at June 30, 2023. In addition to its own global network of offices, ICON can provide service delivery in a total of 93 countries globally, through locally based staff who work from home, and partnerships with local third-party providers. ICON offers a broad range of specialised services to assist pharmaceutical, biotechnology, medical device and government and public health organisations to bring new treatments to market faster. Our services span the entire lifecycle of product development, across a broad range of therapeutic areas, and can be adapted to suit small local trials or large global programs. We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.
ICON services video
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
Organic growth bolstered through a number of strategic acquisitions which have broadened our service portfolio and have added scale to existing services.
ICON has assembled a leadership team with extensive industry experience.
ICON's press releases.
Quarter two 2023 revenue of $2,020.3 million representing an increase of 4.4% on prior year revenue and 4.3% on a constant currency organic basis.
YTD 2023 revenue of $3,998.8 million representing a year on year increase of 4.2% and 4.7% on a constant currency basis.
Updated full-year 2023 financial guidance for revenue by narrowing the revenue range to $8,070 - $8,210 million, representing a year over year increase of 4.3 to 6.1%.